2021 World Conference on Lung Cancer (Posters)-FP08. Lung Stereotactic Body Radiation Therapy for Treatment of Oligoprogressive and Oligorecurrent Metastatic Disease: A Multi-Center Analysis

FP08. Lung Stereotactic Body Radiation Therapy for Treatment of Oligoprogressive and Oligorecurrent Metastatic Disease: A Multi-Center Analysis

Back to course

Video Transcription

Video Summary

The video is a presentation by Dr. Thibaut Thien, a radiation oncologist, discussing the outcomes of lung stereotactic radiation therapy (SPRT) for patients with oligoprogressive and oligo-recurrent intrathoracic disease. The study included 118 patients with a total of 172 target lesions who received SPRT. The results showed excellent local control, with greater than 85% at five years. The median intrathoracic progression-free survival was nine months, and the median overall survival was 40 months, with 12% of patients alive at five years. SPRT was found to be a valuable complement to systemic therapy in this setting.

Asset Subtitle

Sibo Tian

Meta Tag

Speaker Sibo Tian

Topic Multimodality of Advanced Lung Cancer

Keywords

lung stereotactic radiation therapy

oligoprogressive

oligo-recurrent intrathoracic disease

local control

intrathoracic progression-free survival